A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1452-1457

  Hummel, Trent R ^a   Wagner, Lars ^a   Ahern, Charlotte ^b   Fouladi, Maryam ^a   Reid, Joel M ^c   Mcgovern, Renee M ^c   Ames, Matthew M ^c   Gilbertson, Richard J ^d   Horton, Terzah ^b   Ingle, Ashish M ^e   Weigel, Brenda ^f   Blaney, Susan M ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Children's Oncology Group; Pediatric cancer; Temozolomide phase I trial; Vorinostat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HISTONE H3; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; VORINOSTAT;

ADOLESCENT; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRAIN CANCER; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CHOROID PLEXUS CARCINOMA; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; EPENDYMOMA; FATIGUE; FEMALE; GLIOMA; HALF LIFE TIME; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROECTODERM TUMOR; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; RECOMMENDED DRUG DOSE; RECURRENT CANCER; RHABDOID TUMOR; SCHOOL CHILD; SIDE EFFECT; SPINAL CORD CANCER; STOMACH PAIN; TERATOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WEIGHT REDUCTION;

CHILDREN'S ONCOLOGY GROUP; PEDIATRIC CANCER; TEMOZOLOMIDE PHASE I TRIAL; VORINOSTAT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONES; HUMANS; HYDROXAMIC ACIDS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PROMOTER REGIONS, GENETIC; RECURRENCE; SPINAL CORD NEOPLASMS; THROMBOCYTOPENIA; TUMOR SUPPRESSOR PROTEINS;

EID: 84880349569     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24541     Document Type: Article

References (38)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692.
2. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202.
3. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26:1351-1356.
4. Weidle UH, Grossmann A. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000; 20:1471-1485.
5. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-299.
6. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26:5541-5552.
7. Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007; 13:1045-1052.
8. Furchert SE, Lanvers-Kaminsky C, Juurgens H, et al. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120:1787-1794.
9. Sonnemann J, Kumar KS, Heesch S, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28:755-766.
10. Spiller SE, Ravanpay AC, Hahn AW, et al. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neuro-Oncol 2006; 79:259-270.
11. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100:2041-2046.
12. Xu J, Sampath D, Lang FF, et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 2011; 105:241-251.
13. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995; 55:2853-2857.
14. Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neuro-Oncol 2006; 76:313-319.
15. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group. Neuro Oncol 2011; 13:410-416.
16. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002; 20:4684-4691.
17. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer 2007; 110:1542-1550.
18. Barone G, Maurizi P, Tamburrini G, et al. Role of temozolomide in pediatric brain tumors. Childs Nervous Syst 2006; 22:652-661.
19. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006; 42:2335-2342.
20. Durando X, Thivat E, Gilliot O, et al. Temozolomide treatment of an adult with a relapsing medulloblastoma. Cancer Invest 2007; 25:470-475.
21. Hongeng S, Visudtibhan A, Dhanachai M, et al. Treatment of leptomeningeal relapse of medulloblastoma with temozolomide. J Pediatr Hematol/Oncol 2002; 24:591-593.
22. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. [erratum appears in Eur J Cancer 1993; 29A(10):1500]. Eur J Cancer 1993; 29A:940-942.
23. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. [see comment]. Neurology 2007; 68:1831-1836.
24. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. [see comment]. J Clin Oncol 2003; 21:646-651.
25. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro-Oncology 2007; 9:161-168.
26. Khaw SL, Coleman LT, Downie PA, et al. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 2007; 49:808-811.
27. Kuo DJ, Weiner HL, Wisoff J, et al. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol/Oncol 2003; 25:372-378.
28. Skolnik JM, Barrett JS, Jayaraman B, et al. Shortening the timeline of pediatric phase I trials: The rolling six design. J Clin Oncol 2008; 26:190-195.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
30. Parise RA, Holleran JL, Beumer JH, et al. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 840:108-115.
31. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 2000; 17:1551-1557.
32. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25:4806-4812.
33. Horton TM, Thompson PA, Berg SL, et al. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: A Children's Oncology Group Study. J Clin Oncol 2007; 25:4922-4928.
34. Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63:7291-7300.
35. Wen PY, Puduvalli V, Kuhn J, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide in patients with malignant gliomas. J Clin Oncol 2007; 25:84s (abstract 2039).
36. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-3639.
37. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931.
38. Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6:998-1007.